Absorb is non-inferior to Xience in ABSORB-Japan

627

Results from the ABSORB-Japan study, which were presented at the 2015 European Society of Cardiology meeting (ESC, 29 August–1 September, London, UK), indicate that the bioresorbable vascular scaffold (Absorb, Abbott Vascular) is non-inferior to a everolimus-eluting stent with a permanent polymer (Xience, Abbott Vascular). The results have published online in the European Heart Journal.

ABSORB Japan was a multicentre, randomised trial that compared the safety and effectiveness of the bioresorbable vascular scaffold with a permanent polymer everolimus-eluting stent (recognised as the gold standard) for the management of coronary artery disease. The one-year rate of the primary endpoint—target lesion failure—was 4.2% for the scaffold and 3.8% for the everolimus-eluting stent (non-inferiority p<0.0001) and the rate of stent thrombosis was 1.5% for both devices (p=1). Additionally, the major secondary endpoint of angiographic in-segment late lumen loss was 0.13±0.30 vs. 0.12±0.32 , respectively (non-inferiority p<0.0001).


ABSORB-Japan principal investigator, Takeshi Kimura (director, Department of Cardiovascular Medicine, Kyoto University Hospital, Japan) says: “The results of the ABSORB Japan study continue to affirm that Absorb shows strong performance near-term and preserves the vessel for potential future procedures. Fully dissolving heart stents are the next evolution in percutaneous coronary intervention and are designed to leave nothing behind in the body, thus restoring the vessel more naturally over time, which cannot be achieved with a permanent drug eluting stent.”


Last year, results from ABSORB II—the first prospective, randomised, controlled trial comparing the safety and effectiveness of the scaffold to the everolimus-eluting stent—found that the outcomes for the two devices were comparable.